昊海生物科技(06826.HK)附属斥2,500万人币增资亨泰视觉
昊海生物科技(06826.HK)公布,全资子公司昊海发展与金亨泰签署《投资协议》,以1,500万元人民币(下同)购入金亨泰持有的亨泰视觉10%股权,同时以1,000万元增资认购亨泰视觉。完成後,昊海发展持有亨泰视觉55%股权。
另外,昊海控股与亨泰光学及亨泰视觉签署《独家经销合同》,授予亨泰视觉高端角膜塑形用硬性透气接触镜产品於中国内地经销,为期10年,并持续授予亨泰视觉儿童近视管理及控制的光学镜片「贝视得」於中国大陆地区的独家经销权。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.